Efficacy and safety of Herceptin in women with Her2-positive (HER2+) metastatic breast cancer (MBC) who have progressed on a prior herceptin-containing regimen.

被引：0
|
作者：
Gelmon, K [1 ]
Mackey, J [1 ]
Verma, S [1 ]
Gertler, SZ [1 ]
Bangermann, N [1 ]
Klimo, P [1 ]
Schneeweiss, A [1 ]
Bremer, K [1 ]
Soulieres, D [1 ]
Tonkin, K [1 ]
Bell, R [1 ]
Heinrich, B [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
440
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [31] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [32] Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Pusztai, L
    Esteva, FJ
    CANCER INVESTIGATION, 2006, 24 (02) : 187 - 191
  • [33] Results of a phase II trial of Herceptin® plus Xeloda® in patients with previously untreated HER2-positive metastatic breast cancer
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Lil, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    Chen, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S129
  • [34] Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
    Martin-Castillo, Begona
    Lopez-Bonet, Eugeni
    Cuyas, Elisabet
    Vinas, Gemma
    Pernas, Sonia
    Dorca, Joan
    Menendez, Javier A.
    ONCOTARGET, 2015, 6 (32) : 32317 - 32338
  • [35] Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)
    Dhanushkodi, Manikandan
    Iyer, Priya
    Ananthi, Balasubramanian
    Krishnamurthy, Arvind
    Lakshmipathy, K. M.
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (03)
  • [36] Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)
    Manikandan Dhanushkodi
    Priya Iyer
    Balasubramanian Ananthi
    Arvind Krishnamurthy
    K. M. Lakshmipathy
    Indian Journal of Gynecologic Oncology, 2019, 17
  • [37] BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer
    Cocquyt, V. F.
    Martinez-Mena, C. L.
    Martens, M. T.
    D'Hondt, R. G.
    Graas, M-P L.
    Evron, E.
    Fried, G.
    Ben-Baruch, N. E.
    Dijkstra, A. C.
    Van De Walle, E. I.
    CANCER RESEARCH, 2017, 77
  • [38] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Population pharmacokinetics (Pop PK) of MYL-1401O (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer (mBC)
    Owen, Joel
    Rackley, Russell
    Liu, Mark
    Fuentes-Alburo, Adolfo
    Idris, Tazeen
    Loganathan, Subramanian
    Barve, Abhijit
    Waller, Cornelius F.
    Rugo, Hope S.
    CANCER RESEARCH, 2021, 81 (04)
  • [40] Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.
    Johnston, S. R. D.
    Gelmon, K. A.
    Pivot, X. B.
    Gradishar, W. J.
    Conner, A.
    Kothari, D.
    Legenne, P.
    Leigh, M.
    O'Rourke, L.
    Parikh, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345